3
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Cyst
2
Neoplasms
2
Melanoma
2
Stomach Neoplasms
1
Stage IB Cervical Cancer FIGO 2018
1
Spondylitis, Ankylosing
1
Psoriasis
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lupus Erythematosus, Systemic
1
Kidney Neoplasms
1
Inflammatory Bowel Diseases
1
Hepatitis B, Chronic
1
Giant Cell Tumor of Bone
1
Crohn Disease
1
Colitis, Ulcerative
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Bone Neoplasms
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Arthritis, Reactive
1
Interventions
Sorafenib
20
lenvatinib
18
Hepatectomy
17
Blood Specimen Collection
12
Immune Checkpoint Inhibitors
11
Liver Transplantation
9
atezolizumab
8
Surgical Procedures, Operative
7
Radiofrequency Ablation
7
Observation
7
Bevacizumab
6
regorafenib
5
gadolinium ethoxybenzyl DTPA
5
sintilimab
4
donafenib
4
camrelizumab
4
Radiotherapy
4
Magnetic Resonance Spectroscopy
4
tislelizumab
3
spartalizumab
3
Polymerase Chain Reaction
3
Neoadjuvant Therapy
3
Mass Spectrometry
3
Immunohistochemistry
3
Doxorubicin
3
Angiogenesis Inhibitors
3
toripalimab
2
pembrolizumab
2
entecavir
2
apatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Hepatocellular
×
Methods
×
Clear all
NCT07120750
2025-08-13
PRTRAS 001
Shenzhen Third People's Hospital
Not yet recruiting
332 enrolled